A phase I study of APX001 (oral) for the treatment of candidiasis

Trial Profile

A phase I study of APX001 (oral) for the treatment of candidiasis

Planning
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs APX 001 (Primary)
  • Indications Aspergillosis; Candidiasis; Mycoses
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Sep 2016 New trial record
    • 12 Sep 2016 According to an Amplyx Pharmaceuticals media release, company plans to initiate this phase 1 study of oral APX001 in late 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top